-
Posted by
Two Blokes Jun 13 -
Filed in
Stock
-
5 views
Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data supports continued development, though competition and high efficacy benchmarks in B-cell malignancies remain challenges. Financially, Schrödinger's software business is growing steadily, with strong cash reserves and manageable risks, supporting ongoing R&D investment.
